RELAPSED ADULT AML
Clinical trials for RELAPSED ADULT AML explained in plain language.
Never miss a new study
Get alerted when new RELAPSED ADULT AML trials appear
Sign up with your email to follow new studies for RELAPSED ADULT AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on stubborn leukemia in first safety test
Disease control Recruiting nowThis early-phase study tests whether specially engineered immune cells (CD19 CAR-T cells) are safe for adults with relapsed or treatment-resistant acute myeloid leukemia (AML) that carries a CD19 marker. Only 5 participants will be enrolled. The goal is to monitor side effects an…
Matched conditions: RELAPSED ADULT AML
Phase: PHASE1 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated May 01, 2026 16:00 UTC
-
New hope for tough leukemia: 3-Drug combo trial opens
Disease control Recruiting nowThis study tests a combination of three drugs (venetoclax, chidamide, and azacitidine) in adults whose acute myeloid leukemia has returned or not responded to prior treatment. The goal is to see if this mix can safely achieve remission. About 30 participants will receive the trea…
Matched conditions: RELAPSED ADULT AML
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated May 01, 2026 16:00 UTC
-
Engineered immune cells take on stubborn leukemia in early trial
Disease control Recruiting nowThis early-stage trial tests a new treatment for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses specially engineered natural killer (NK) cells designed to target and destroy leukemia cells. The main goals are t…
Matched conditions: RELAPSED ADULT AML
Phase: PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC